20 April 2026
Lilly to acquire Kelonia Therapeutics for in vivo CAR‑T platform
Buyer will acquire a clinical-stage in vivo CAR-T developer for up to $7B (incl. $3.25B upfront). Lead KLN-1010 (lentiviral anti-BCMA) showed promising Phase 1 ASH data; close expected H2 2026.